Abstract
Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been consistently underrepresented in clinical trials. Anti- HER-2 therapy among an elderly population was reviewed including approaches for making treatment effective.
Keywords: Anti-HER2 therapy, breast cancer, HER-2/neu, elderly.
Reviews on Recent Clinical Trials
Title:Anti-HER2 Therapy in Elderly Breast Cancer Patients
Volume: 9 Issue: 4
Author(s): Masataka Sawaki
Affiliation:
Keywords: Anti-HER2 therapy, breast cancer, HER-2/neu, elderly.
Abstract: Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been consistently underrepresented in clinical trials. Anti- HER-2 therapy among an elderly population was reviewed including approaches for making treatment effective.
Export Options
About this article
Cite this article as:
Sawaki Masataka, Anti-HER2 Therapy in Elderly Breast Cancer Patients, Reviews on Recent Clinical Trials 2014; 9 (4) . https://dx.doi.org/10.2174/1574887109666141127102035
DOI https://dx.doi.org/10.2174/1574887109666141127102035 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Reviews on Recent Clinical Trials Exosomal MicroRNAs in Tumoral U87 MG Versus Normal Astrocyte Cells
MicroRNA Evaluation of Anticancer Activities of Gallic Acid and Tartaric Acid Vectorized on Iron Oxide Nanoparticles
Drug Delivery Letters Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Detecting Personalized Determinants During Drug Treatment from Omics Big Data
Current Pharmaceutical Design Topics of Physiological and Pathophysiological Functions of Lymphatics
Current Molecular Medicine Meet Our Editorial Board Member
Current Medicinal Chemistry Type 2 Diabetes and Obesity Metabolic Interactions: Common Factors for Breast Cancer Risk and Novel Approaches to Prevention and Therapy
Current Diabetes Reviews Multifunctional Superparamagnetic Nanoparticles: From Synthesis to siRNA Delivery
Current Pharmaceutical Design Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Heparan Sulfate Proteoglycans, Tumour Progression and the Cancer Stem Cell Niche
Current Cancer Therapy Reviews Editorial A New Year of Excellence
Current Molecular Medicine Long Term Prognosis in IgG4-Related Systemic Disease (ISD)
Current Immunology Reviews (Discontinued) The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Research and Development in Betulin and Betulinic Acid Derived Triterpenoids
Mini-Reviews in Organic Chemistry Recent Advances in Peroxisome Proliferator-Activated Receptor Science
Current Medicinal Chemistry Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Investigation of Novel Chemical Inhibitors of Human Lysosomal Acid Lipase: Virtual Screening and Molecular Docking Studies
Combinatorial Chemistry & High Throughput Screening GnRH-Agonist Triggering to Avoid Ovarian Hyperstimulation Syndrome: A Review of the Evidence
Current Drug Targets